-
公开(公告)号：US07015193B2
公开(公告)日：2006-03-21
申请号：US10125950
申请日：2002-04-19
CPC分类号： A61K38/4846 , A61K9/127 , C07K14/755 , Y10S514/802 , Y10S514/834
摘要： Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.
-
公开(公告)号：US20100261198A1
公开(公告)日：2010-10-14
申请号：US12681232
申请日：2008-10-03
申请人： Kenneth G. Mann , Saulius Butenas , Anetta Undas
发明人： Kenneth G. Mann , Saulius Butenas , Anetta Undas
IPC分类号： G01N33/573 , G01N33/53
CPC分类号： C12Q1/56 , G01N33/86 , G01N2800/2871 , G01N2800/323 , G01N2800/324 , G01N2800/325
摘要： The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.
摘要翻译： 本发明提供了使用基于抗体的凝血时间延长测定法在样品中检测因子XIa或组织因子（TF）活性的组合物和方法。 本发明提供了使用荧光底物检测样品中FXIa或TF活性的方法。 本文进一步提供的是FXIa和/或TF与炎症，急性冠状动脉综合征（ACS），心肌梗塞，冠状动脉疾病（CAD），心力衰竭，主动脉瓣狭窄，中风或短暂性脑缺血发作的升高水平之间的相关性。 FXIa和TF活动的频率在冠状动脉疾病稳定且无心肌梗死史的个体中显着降低。 健康人中没有观察到FXIa或TF活性。
-
公开(公告)号：US08574849B2
公开(公告)日：2013-11-05
申请号：US12681232
申请日：2008-10-03
申请人： Kenneth G. Mann , Saulius Butenas , Anetta Undas
发明人： Kenneth G. Mann , Saulius Butenas , Anetta Undas
IPC分类号： G01N33/53
CPC分类号： C12Q1/56 , G01N33/86 , G01N2800/2871 , G01N2800/323 , G01N2800/324 , G01N2800/325
摘要： The invention provides compositions and methods for the detection of Factor XIa or Tissue Factor (TF) activity in a sample using an antibody based clotting time prolongation assay. The invention provides methods for detection of FXIa or TF activity in a sample using a fluorogenic substrate. Further provided herein is a correlation between elevated levels of FXIa and/or TF with inflammation, acute coronary syndrome (ACS), myocardial infarction, coronary artery disease (CAD), heart failure, aortic stenosis, stroke, or transient ischemic attack. The frequency of FXIa and TF activity was substantially lower in individuals with stable coronary artery disease and no history of myocardial infarction. No FXIa or TF activity was observed in healthy individuals.
摘要翻译： 本发明提供了使用基于抗体的凝血时间延长测定法在样品中检测因子XIa或组织因子（TF）活性的组合物和方法。 本发明提供了使用荧光底物检测样品中FXIa或TF活性的方法。 本文进一步提供的是FXIa和/或TF与炎症，急性冠状动脉综合征（ACS），心肌梗塞，冠状动脉疾病（CAD），心力衰竭，主动脉瓣狭窄，中风或短暂性脑缺血发作的升高水平之间的相关性。 FXIa和TF活动的频率在冠状动脉疾病稳定且无心肌梗死史的个体中显着降低。 健康人中没有观察到FXIa或TF活性。
-
4.发明授权Peptidomimetics containing 6-peptidylamino-1-naphthalenesulfonamide moieties 失效含有6-肽基氨基-1-萘磺酰胺部分的肽模拟物公开(公告)号：US06566493B1
公开(公告)日：2003-05-20
申请号：US09308437
申请日：1999-09-09
申请人： Saulius Butenas , Kenneth G. Mann
发明人： Saulius Butenas , Kenneth G. Mann
IPC分类号： C07K702
CPC分类号： C07K7/06 , A61K38/00 , C07K5/0606 , C07K5/06069 , C07K5/06086 , C07K5/06104 , C07K5/06113 , C07K5/0808 , C07K5/0815 , C07K5/0819 , C07K5/101 , C07K5/1013 , C07K5/1019 , C07K5/1024
摘要： Compounds of the following formula are disclosed, wherein R1 is a peptide and R2 is an amino acid or peptide as disclosed herein: The compounds are inhibitors of activated protein C.
摘要翻译： 公开了下式的化合物，其中R1是肽，R2是本文公开的氨基酸或肽：化合物是活化蛋白C的抑制剂
-
5.发明授权6-peptidylamino-1-naphthalenesulfonamides useful as fluorogenic proteolytic enzyme substrates 失效用作荧光蛋白水解酶底物的6-肽基氨基-1-萘磺酰胺
公开(公告)号：US5399487A
公开(公告)日：1995-03-21
申请号：US27294
申请日：1993-03-04
IPC分类号： C07D209/48 , C07K5/083 , C12Q1/37 , C12Q1/56 , C07D257/08 , C07D273/04 , C12Q1/00
CPC分类号： C07D209/48 , C07K5/0808 , C12Q1/37 , C12Q1/56 , C12Q2337/30 , Y10S514/822
摘要： The present invention encompasses compounds of formula I: ##STR1## and the pharmaceutically acceptable non-toxic salts thereof; wherein R.sub.1 is hydrogen, lower alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, or phenylalkyl;R.sub.2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, cycloalkylalkyl, or phenylalkyl; orNR.sub.1 R.sub.2 forms a nitrogen heterocycle; andR.sub.3 is hydrogen, an amino acid or a peptide residue.These compounds may be employed as substrates in assays for determining proteolytic enzyme activity or as enzyme inhibitors. The invention also encompasses methods for determining proteolytic enzyme activity using the compounds of formula I.
摘要翻译： 本发明包括式I化合物及其药学上可接受的无毒盐; 其中R1是氢，低级烷基，烯基，炔基，环烷基，烷基环烷基，环烷基烷基或苯基烷基; R2是氢，烷基，烯基，炔基，环烷基，烷基环烷基，环烷基烷基或苯基烷基; 或NR1R2形成氮杂环; 并且R 3是氢，氨基酸或肽残基。 这些化合物可以用作用于测定蛋白水解酶活性的测定中的底物或作为酶抑制剂。 本发明还包括使用式I化合物测定蛋白水解酶活性的方法。
-
公开(公告)号：US07235377B2
公开(公告)日：2007-06-26
申请号：US10865608
申请日：2004-06-09
申请人： Kenneth G. Mann , Kathleen Brummel
发明人： Kenneth G. Mann , Kathleen Brummel
IPC分类号： C12Q1/56
CPC分类号： G01N33/86 , G01N2800/52
摘要： The instant invention describes a method for establishing the hemostatic competence of blood, wherein the steps of the method include obtaining a blood sample from a subject, contacting the blood sample with an effective amount of tissue factor under conditions conducive to coagulating blood; and detecting the amount of thrombin in the blood sample at a pre-determined time point. The invention also describes a method for testing the capacity of an individual subject to produce thrombin, wherein the steps of the method include obtaining a blood sample from the subject; contacting the blood sample with an effective amount of tissue factor under conditions conducive to coagulating blood; and detecting the amount of thrombin produced in the blood sample at a pre-determined time point.
摘要翻译： 本发明描述了建立血液止血能力的方法，其中所述方法的步骤包括从受试者获得血液样品，在有利于血液凝结的条件下使血液样品与有效量的组织因子接触; 以及在预先确定的时间点检测血液样品中凝血酶的量。 本发明还描述了一种用于测试个体受试者产生凝血酶的能力的方法，其中所述方法的步骤包括从受试者获得血液样品; 在有利于凝血的条件下使血液样品与有效量的组织因子接触; 并且在预定时间点检测在血液样品中产生的凝血酶的量。
-
7.发明申请Highly Sensitive Immunoassays and Antibodies for Detection of Blood Factor VIII 有权用于检测血液因子VIII的高度敏感的免疫测定和抗体公开(公告)号：US20090215070A1
公开(公告)日：2009-08-27
申请号：US11988518
申请日：2006-07-13
CPC分类号： G01N33/86 , C07K16/36 , C07K16/40 , G01N2333/755 , Y10S435/962 , Y10T436/25125 , Y10T436/25375
摘要： Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.
摘要翻译： 公开了选择性结合凝血因子FVIII的抗体以及包含这些抗体的高度敏感的免疫学测定。 优选的测定可以检测低于正常生理水平约3500倍的FVIII，并且具有广泛的应用，包括精确监测用于治疗凝血障碍的药物产品中的FVIII浓度，以及测定人类患者血浆中的FVIII水平， 包括那些血友病血液凝固症。
-
公开(公告)号：US06566140B2
公开(公告)日：2003-05-20
申请号：US09844209
申请日：2001-04-27
IPC分类号： G01N3386
CPC分类号： G01N33/86 , G01N2333/811
摘要： The present invention provides methods for inhibiting blood clotting. In general, the methods include adding corn trypsin inhibitor (CTI) to blood or a blood product in an amount sufficient to inhibit the clotting. The CTI can be used alone or in combination with other anti-coagulants. In one aspect, the invention features plasma clotting assays featuring substantially prolonged clotting times. Clotting assays using whole or minimally altered blood are also provided. Further provided are methods for storing blood or blood products at low temperature with the CTI.
-
公开(公告)号：US06365364B1
公开(公告)日：2002-04-02
申请号：US09377250
申请日：1999-08-19
IPC分类号： C12Q156
CPC分类号： C12N9/6435 , A61K31/00 , A61K47/64 , C12Y304/21007
摘要： The present invention features isolated angiogenesis inhibitors having a molecular weight of between about 40 kDa to 50 kDa and having an amino acid sequence substantially similar to that of the amino acid sequence shown in SEQ ID NO. 2 or SEQ ID NO. 3. Further provided are methods of making and using the angiogenesis inhibitors, e.g., to inhibit vascularization or to block osteonectin and plasminogen interaction.
摘要翻译： 本发明具有分子量在约40kDa至50kDa之间且具有基本上类似于SEQ ID NO：1所示氨基酸序列的氨基酸序列的分离的血管生成抑制剂。 2或SEQ ID NO。 进一步提供制备和使用血管生成抑制剂的方法，例如抑制血管形成或阻断骨粘连蛋白和纤溶酶原相互作用。
-
公开(公告)号：US20090298103A1
公开(公告)日：2009-12-03
申请号：US12454677
申请日：2009-05-20
CPC分类号： G01N33/6893 , G01N33/86 , G01N2800/224 , G01N2800/50
摘要： Featured are methods for assessing hemostatic risk including the risk for ACS. Such methods include acquiring blood/plasma composition based on a biological sample obtained from a subject, determining parameters associated with blood clotting, simulating in silico blood clotting using the determined parameters and comparing the results of such simulation to a reference and to determine the hemostatic risk from said comparing. In further embodiments, such methods further include selecting a treatment regime or protocol based on the results of such comparing. In yet further embodiments, such methods further include assessing the efficacy of medicants, drugs and the like of a given treatment protocol such as by simulating in silico the application of such medicants, drugs and the like.
摘要翻译： 特色是评估止血风险的方法，包括ACS的风险。 这样的方法包括基于从受试者获得的生物样品获得血液/血浆组合物，确定与血液凝结相关的参数，使用确定的参数模拟计算机血液凝固，并将这种模拟的结果与参考值进行比较并确定止血风险 从比较。 在另外的实施方案中，这些方法还包括基于这种比较的结果选择治疗方案或方案。 在进一步的实施方案中，这些方法还包括评估给定治疗方案的药物，药物等的功效，例如通过模拟这种药物，药物等的应用。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.026 秒)
